Amylyx Pharmaceuticals, Inc. (AMLX) (“Amylyx” or the “Company”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...

高盛分析师指出，迄今为止的数据在很大程度上支持avexitide有潜力帮助PBH患者。积极展望的一个关键点是与FDA就提议的主要终点达成一致，即减少低血糖事件，这被认为可以降低监管风险。然而，关于Amylyx在PBH市场机会规模的争论仍在继续，因为该药物将是这一特定适应症的首个同类药物。

CAMBRIDGE, Mass., November 27, 2024--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today announced that management will participate in the 7th Annual ...

This page features the latest news about the Amylyx Pharmaceuticals stock. Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA for the ...

Baird的最新升级与InvestingPro的一些有趣财务指标相一致。Amylyx Pharmaceuticals的市值为3.2407亿美元，反映了市场对公司的当前估值。如果avexitide的开发按照Baird的预期进展，这一数字可能会发生重大变化。

As previously reported, BofA analyst Charlie Yang upgraded Amylyx (AMLX) to Buy from Neutral with a price target of $10, up from $4.20, based on the firm’s view of avexitide, a drug being ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the third quarter ended September 30, 2024.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. TipRanks is the most comprehensive data set of sell side ...

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS).